Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively. Browse Full Report With TOC @ http://www.researchmoz.us/pharmapoint-gastric-and-gastroesophageal-junction-adenocarcinoma-global-drug-forecast-and-market-analysis-to-2024-report.html
http://www.researchmoz.us/pharmapoint-gastric-and-gastroesophageal-junction-adenocarcinoma-global-drug-forecast-and-market-analysis-to-2024-report.html
No comments:
Post a Comment